Prolonged Clinical Follow-up of OPTIMA-5

PHASE4CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

October 29, 2021

Primary Completion Date

September 14, 2023

Study Completion Date

October 1, 2023

Conditions
ST-segment Elevation Myocardial Infarction (STEMI)
Interventions
DRUG

Recombinant Staphylokinase

Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction

DRUG

Normal Saline

Intravenous injection of normal saline is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction

Trial Locations (8)

210029

The First Affiliated Hospital of Nanjing Medical University, Nanjing

Unknown

Changzhou Second People's Hospital, Changzhou

The second Affiliated Hospital of Dalian Medical University, Dalian

Huai 'an Second People's Hospital affiliated to Nanjing Medical University, Huai'an

Lianyungang First People's Hospital, Lianyungang

Taizhou People's Hospital, Taizhou

Affiliated Hospital of Jiangnan University, Wuxi

The Second Affiliated Hospital of Zhejiang University Medical College, Zhejiang

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT05649696 - Prolonged Clinical Follow-up of OPTIMA-5 | Biotech Hunter | Biotech Hunter